DelSiTech Ltd.
http://www.delsitech.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DelSiTech Ltd.
From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug Development
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.
Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Medical Devices
- Implantable Devices